Benserazide hydrochloride (Synonyms: Serazide; Ro 4-4602)

Name: Benserazide hydrochloride
Brand: MedChemExpress
SKU: HY-B0404A
Rating: 4.5 (3 reviews)

Cat. No.: HY-B0404A Purity: 99.87%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC).

For research use only. We do not sell to patients.

Benserazide hydrochloride Chemical Structure

CAS No. : 14919-77-8

Size	Price	Stock	Quantity

Free Sample (0.1 - 0.5 mg)		Apply Now
Solid + Solvent
10 mM * 1 mL in DMSO ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
500 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
1 g	USD 79	In-stock	Estimated Time of Arrival: December 31
5 g	USD 237	In-stock	Estimated Time of Arrival: December 31
10 g		Get quote
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of Benserazide hydrochloride:

Benserazide Get quote
Benserazide-d₃ hydrochloride Get quote

3 Publications Citing Use of MCE Benserazide hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Benserazide hydrochloride (Serazide) is commonly used in Parkinson's disease and is an inhibitor of peripheral aromatic L-amino acid decarboxylase (AADC)^[1].

In Vitro

Benserazide hydrochloride (BH) and Levodopa (LD) individually and in combination (Benserazide hydrochloride + LD) (25 μM; 0 hour, 12 hours, 24 hours and 168 hours; SH-SY5Y) treatment inhibit protein aggregation and have the ability to minimise the amyloid-induced cytotoxicity in human neuroblastoma cell line. Benserazide hydrochloride and LD both can act as efficient inhibitors of the formation of cytotoxic HSA aggregates, and the inhibitory effects are more pronounced when both of these drugs are added simultaneously^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	SH-SY5Y cells
Concentration:	25 μM
Incubation Time:	0 hour, 12 hours, 24 hours and 168 hours
Result:	Enhanced cell viability, and inhibited the formation of cytotoxic human serum albumin (HSA) aggregates.

In Vivo

Benserazide (5-50 mg/kg; intraperitoneal injection; male Wistar rats) treatment of 6-OHDA-lesioned rats increases exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels are significantly prolong by Benserazide dose-dependently. The AADC activity in the denervates striatal tissues shows a significant decrease by 10 mg/kg and 50 mg/kg Benserazide. Benserazide reduces the central AADC activity in the striatum of rats with nigrostriatal denervation, which leads to changes in the metabolism of exogenous L-DOPA^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Wistar rats with 6-hydroxydopamine (6-OHDA) (8 Ag/4 Al)^[1]
Dosage:	5 mg/kg, 10 mg/kg or 50 mg/kg (Pharmacokinetic study)
Administration:	Intraperitoneal injection
Result:	Increased in exogenous L-DOPA-derived extracellular DA levels, the time to reach the peak DA levels were significantly prolonged in a dose-dependent fashion. The AADC activity in the denervated striatal tissues showed a significant decreased by 10 mg/kg and 50 mg/kg.

Clinical Trial

Molecular Weight

293.70

Formula

C₁₀H₁₆ClN₃O₅

CAS No.

14919-77-8

Appearance

Solid

Color

White to off-white

SMILES

NC(CO)C(NNCC1=CC=C(O)C(O)=C1O)=O.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (340.48 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : ≥ 50 mg/mL (170.24 mM)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.4048 mL	17.0242 mL	34.0483 mL
5 mM	0.6810 mL	3.4048 mL	6.8097 mL
10 mM	0.3405 mL	1.7024 mL	3.4048 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months (sealed storage, away from moisture). When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (7.08 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL (340.48 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.87%

Select Batch:

Data Sheet (277 KB) SDS (0 KB)

COA (247 KB) HNMR (255 KB) LCMS (257 KB)

Handling Instructions (2659 KB)

References

[1]. Shen H, et al. Effects of benserazide on L-DOPA-derived extracellular dopamine levels and aromatic L-amino acid decarboxylase activity in the striatum of 6-hydroxydopamine-lesioned rats. Tohoku J Exp Med. 2003 Mar;199(3):149-59. [Content Brief]

[2]. Chandel TI, et al. A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin. Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):275-285. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O / DMSO	1 mM	3.4048 mL	17.0242 mL	34.0483 mL	85.1209 mL
	5 mM	0.6810 mL	3.4048 mL	6.8097 mL	17.0242 mL
	10 mM	0.3405 mL	1.7024 mL	3.4048 mL	8.5121 mL
	15 mM	0.2270 mL	1.1349 mL	2.2699 mL	5.6747 mL
	20 mM	0.1702 mL	0.8512 mL	1.7024 mL	4.2560 mL
	25 mM	0.1362 mL	0.6810 mL	1.3619 mL	3.4048 mL
	30 mM	0.1135 mL	0.5675 mL	1.1349 mL	2.8374 mL
	40 mM	0.0851 mL	0.4256 mL	0.8512 mL	2.1280 mL
	50 mM	0.0681 mL	0.3405 mL	0.6810 mL	1.7024 mL
	60 mM	0.0567 mL	0.2837 mL	0.5675 mL	1.4187 mL
	80 mM	0.0426 mL	0.2128 mL	0.4256 mL	1.0640 mL
	100 mM	0.0340 mL	0.1702 mL	0.3405 mL	0.8512 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Benserazide hydrochloride Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Benserazide14919-77-8Serazide Ro 4-4602OthersInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Benserazide hydrochloride (Synonyms: Serazide; Ro 4-4602)

Customer Review

Other Forms of Benserazide hydrochloride:

Benserazide hydrochloride Related Antibodies

3 Publications Citing Use of MCE Benserazide hydrochloride

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

Benserazide hydrochloride Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Benserazide hydrochloride Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

Request for HNMR Report